Matthias Aizenberg

Glioblastoma care has long run up against a biological wall that blunts even the best therapies, and a new approach that pries open that wall just long enough to let drugs in now looks like a genuine shift rather than a lab curiosity. Patients still face a dire prognosis despite aggressive surgery

In a world where patients often wait nearly a year for life-saving drugs to gain approval, a groundbreaking initiative by the FDA is slashing that timeline to mere weeks, promising a dramatic shift in biopharma. The Commissioner’s National Priority Voucher (CNPV) pilot program is not just speeding

I'm thrilled to sit down with Ivan Kairatov, a biopharma expert with a profound understanding of technology and innovation in the healthcare industry. With a robust background in research and development, Ivan has been at the forefront of exploring how artificial intelligence can transform

In a world where Alzheimer’s disease continues to challenge medical science with its relentless progression and devastating impact on millions of lives, the search for effective treatments remains a top priority for researchers and pharmaceutical companies alike. Recent developments have sparked

Japan stands at the forefront of a digital transformation that is reshaping the very foundation of its healthcare system, with the My Number card serving as a pivotal tool in this evolution, initially designed for social security and tax purposes. This national identification card has now become an

What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in tech and innovation within the healthcare industry. With a strong background in research and development, Ivan brings a unique perspective on the evolving landscape of telehealth and pharmaceutical

The landscape of oncology treatment is witnessing a transformative shift with Johnson & Johnson (J&J) securing a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for its groundbreaking therapy, TALVEY (talquetamab). This approval for use within the

In a landscape where lung cancer remains one of the most challenging diseases to treat, particularly for rare subsets of patients, a new development has sparked hope among clinicians and affected individuals alike. Bayer’s recently approved drug, sevabertinib, marketed as Hyrnuo, has gained

The pharmaceutical landscape is on the brink of a seismic shift with the introduction of the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, a bold initiative designed to cut the review timeline for drug and biological product applications from the standard 10-12 months down to